Ewing Sarcoma
A highly aggressive pediatric bone and soft tissue cancer characterized by small round blue cells and a t(11;22) translocation, requiring intensive systemic and local therapy.
Emergency Management: Spinal cord compression from vertebral body involvement requires immediate high-dose dexamethasone and emergent radiation or decompressive surgery.
Ewing sarcoma is a rare, highly malignant bone and soft tissue tumor that typically affects children and young adults. It most commonly arises in the diaphysis of long bones (such as the femur) or flat bones (such as the pelvis or scapula). It is characterized by small round blue cells on histology and is strongly associated with the t(11;22)(q24;q12) chromosomal translocation.
Detailed Overview
Ewing sarcoma represents the second most common primary malignant bone tumor in children and adolescents, following osteosarcoma. The disease is driven by a specific gene fusion, most frequently EWSR1-FLI1, which acts as an aberrant transcription factor promoting oncogenesis. Because it is highly aggressive, micrometastatic disease is assumed to be present at diagnosis in most patients, necessitating systemic chemotherapy in addition to local control measures (surgery and/or radiation). Advances in multidisciplinary therapy have improved the 5-year survival rate for localized disease to over 70%, though metastatic disease still carries a poor prognosis.
Epidemiology & Demographics
Incidence is roughly 1-3 cases per 1 million children per year. Peak incidence occurs between ages 10 and 20 years. It is more common in males (M:F ratio of 1.5:1) and significantly more frequent in individuals of European descent compared to African or Asian descent.
Etiological Mechanism
The primary etiology is a somatic chromosomal translocation. Over 85% of cases are caused by the t(11;22)(q24;q12) translocation, which fuses the EWSR1 gene on chromosome 22 with the FLI1 gene on chromosome 11, producing the oncogenic EWSR1-FLI1 fusion protein.
Primary Causes
["Genetic Translocation: t(11;22)(q24;q12) leading to EWSR1-FLI1 fusion.", "Other variants: t(21;22) producing EWSR1-ERG fusion (about 10% of cases)."]
The EWSR1-FLI1 fusion protein functions as an aberrant transcription factor that dysregulates target genes involved in cell cycle progression, apoptosis avoidance, and cellular differentiation. This leads to the uninhibited proliferation of primitive mesenchymal stem cells or neural crest cells, forming a tumor composed of sheets of uniform, small, round cells with scant cytoplasm (small round blue cell tumor). The tumor expansively destroys host bone, often breaking through the cortex to form a large soft tissue mass, and spreads hematogenously to lungs and other bones.
Diagnostic Criteria & Guidelines
Diagnosis requires biopsy confirming a small round blue cell tumor. Immunohistochemistry typically shows strong membrane positivity for CD99 (MIC2). Definitive molecular diagnosis is made via FISH or RT-PCR demonstrating the EWSR1-FLI1 (or variant) translocation.
Standard treatment uses a multidisciplinary approach: neoadjuvant chemotherapy (e.g., VDC/IE regimen: Vincristine 1.5 mg/m2, Doxorubicin 75 mg/m2, Cyclophosphamide 1200 mg/m2 alternating with Ifosfamide 1800 mg/m2/day x 5 days and Etoposide 100 mg/m2/day x 5 days) every 2 weeks for 14 cycles. Local control occurs around week 12 via wide surgical excision and/or definitive radiotherapy (typically 45-50.4 Gy to the tumor volume).
Second-Line & Adjunctive Therapy
For relapsed or refractory disease: Regimens include Irinotecan (50 mg/m2/day x 5 days) + Temozolomide (100 mg/m2/day x 5 days), or High-Dose Chemotherapy with autologous stem cell rescue. Clinical trials testing targeted agents or immunotherapies are recommended.
Surgical & Procedural Management
Wide local excision with negative margins, often requiring limb-salvage reconstruction (endoprosthesis or allograft). Amputation may be necessary for massive tumors or when nerves/vessels are extensively involved.
Patient Counseling & Advice
Discuss the necessity of intensive, multi-modal treatment and prolonged hospital stays. Counsel on fertility preservation prior to starting alkylator-heavy chemotherapy, and long-term risks of secondary cancers and cardiac dysfunction.
Follow-Up & Monitoring Schedule
Surveillance includes history, physical exam, plain films of primary site, and chest CT every 3 months for the first 2-3 years, then every 6 months for years 4-5, then annually. Echocardiogram periodically to monitor doxorubicin cardiotoxicity.
Preventive Strategies
No known preventive measures, as this is a sporadic genetic event.
Localized disease has a 70-75% 5-year survival rate. Metastatic disease at presentation (especially bone/marrow metastases) has a poor prognosis, with a 5-year survival rate of <30%.